Biocon Arm Gets Us Fda Nod For Yesafilli Enters Us Opthalmology Market

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Biocon Arm Gets US FDA Nod for Yesafilli, Enters US Opthalmology Market

ri-calendar-2-lineMay 21, 2024

By: BlinkX Research Team

FbkFbkTwitterTelegram

Biocon Biologics Limited, a wholly owned subsidiary of Biocon Limited announced that the US Food and Drug Administration has approved the Company’s first-to-file application for Yesafili, an interchangeable biosimilar aflibercept.

 

Key Takeaways from Biocon Biologics:

 

  • Biocon Biologics receives US FDA approval for Yesafili.
  • Biocon Biologics’ expansion into the ophthalmology therapeutic area in the US and UK.
  • Data shows YESAFILI has comparable quality, safety, and efficacy to Eylea.

 

The approval marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the US following a steady track record of approval in Europe and the UK where it was the first biosimilar aflibercept to be approved. 

 

YESAFILI is a vascular endothelial growth factor inhibitor used to treat different ophthalmology conditions. According to data, YESAFILI has comparable quality, safety, and efficacy to Eylea. 

 

YESAFILI is used in the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema and visual impairment due to myopic choroidal neovascularization. 

 

About Biocon Biologics Limited:

 

Biocon Biologics Limited is a leading global company that offers a large portfolio of monoclonal antibodies, insulins, and conjugated proteins. It has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including four in the US and six in Canada, Biocon Biologics has a robust pipeline of 20 biosimilar assets across multiple therapy areas.

 

Read More About the Share Market Today Here!

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions